Christiana Stamoulis - 15 Dec 2025 Form 4 Insider Report for Keenova Therapeutics plc

Role
President and CFO
Signature
/s/ Mark Tyndall, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
15 Dec 2025
Net transactions value
$0
Form type
4
Filing time
17 Dec 2025, 18:00:12 UTC
Previous filing
22 Oct 2025
Next filing
23 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Stamoulis Christiana President and CFO 675 MCDONNELL BLVD., HAZELWOOD /s/ Mark Tyndall, Attorney-in-Fact 17 Dec 2025 0001502917

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction Ordinary Shares Options Exercise +30,335 30,335 15 Dec 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction Restricted Stock Units Options Exercise $0 -30,335 -33% $0.000000 60,672 15 Dec 2025 Ordinary Shares 30,335 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU.
F2 On September 23, 2025, the reporting person was granted 91,007 RSUs vesting ratably on each of December 15, 2025, December 15, 2026 and December 15, 2027, subject to the Reporting Person's continued service through such date. The number of RSUs held by the reporting person is subject to adjustment in connection with the separation of Par Health, Inc. ("Par Health") from the Issuer on November 10, 2025 pursuant to the terms of the Employee Matters Agreement by and between the Issuer and Par Health.

Remarks:

This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.